Regen BioPharma Inc (RGBP)

[soupoftheday]

Patents Assigned to Regen BioPharma, Inc

https://patents.justia.com/assignee/regen-biopharma-inc

STIMULATION OF T REGULATORY CELLS BY CANNABIDIOL AS A MEANS OF TREATING ARTHRITIS AND AUTOIMMUNITY
Publication number: 20210059962
Abstract: Disclosed are means, methods, and compositions of matter for stimulation of T regulatory (Treg) cells by cannabidiol. In one embodiment, administration of cannabidiol is performed in an animal suffering from autoimmunity. In situations of autoimmunity, cannabidiol induces generation of Treg cells while other agents or therapies may be used to expand such cells in vitro and/or in vivo. In some embodiments the administration of cannabidiol is performed together with agents such as low dose interleukin-2 in order to treat inflammatory conditions such as arthritis or other conditions associated with reduction in Treg cells such as pregnancy failure, type 1 diabetes, or graft versus host disease.
Type: Application
Filed: September 2, 2020
Publication date: March 4, 2021
Applicant: Regen Biopharma, Inc.
Inventors: Thomas Ichim, David Koos

Modulation of NR2F6 and methods and uses thereof
Patent number: 9091696
Abstract: The application provides methods of modulating NR2F6 in a cell or animal in need thereof by administering an effective amount of a NR2F6 modulator.
Type: Grant
Filed: October 15, 2012
Date of Patent: July 28, 2015
Assignee: Regen Biopharma, Inc.
Inventors: Christine Victoria Ichim, Richard Alexander Wells

CELLS, COMPOSITIONS, AND TREATMENT METHODS FOR STIMULATION OF HEMATOPOIESIS
Publication number: 20150037303
Abstract: The invention discloses novel methods, compositions of matter, and kits for the treatment of disorders affecting the hematopoietic system. Patients are administered an autologous cellular mixture derived from adipose stromal vascular fraction, said cellular mixture comprising endothelial cells, endothelial progenitor cells, T regulatory cells, monocytes, and hematopoietic stem cells. In one embodiment, treatment is provided for patients suffering from inflammatory disorders including aplastic anemia.
Type: Application
Filed: August 1, 2013
Publication date: February 5, 2015
Applicant: Regen BioPharma, Inc
Inventors: Thomas Ichim, David Koos

CANCER THERAPY BY EX VIVO ACTIVATED AUTOLOGOUS IMMUNE CELLS
Publication number: 20140065096
Abstract: Disclosed are therapeutic methods for ex-vivo activation of immune cells from a cancer patient for the purpose of inducing tumor regression and/or suppressing metastasis and/or tumor recurrence. In one embodiment mononuclear cells of a patient are isolated from peripheral blood and activated by a combination of innate immune system activators together with means allowing for T cell activation.
Type: Application
Filed: August 2, 2013
Publication date: March 6, 2014
Applicant: Regen BioPharma, Inc.
Inventors: Thomas Ichim, David Koos

ACCELERATION OF HEMATOPOIETIC RECONSTITUTION BY PLACENTAL ENDOTHELIAL AND ENDOTHELIAL PROGENITOR CELLS
Publication number: 20130309210
Abstract: Compositions useful for treatment of patients needing hematopoietic stimulation. In one embodiment patients are administered a cellular mixture derived from allogeneic placenta, said cellular mixture comprising substantially of endothelial cells and endothelial progenitor cells.
Type: Application
Filed: May 20, 2013
Publication date: November 21, 2013
Applicant: Regen BioPharma, Inc
Inventor: Thomas Ichim